Breadth of RCC Treatment Options Includes Novel Agents and Combo Strategies
Published: Monday, Dec 02, 2019
Kathryn E. Beckermann, MD, PhD
A slew of monotherapy and combination approvals has reshaped the frontline treatment landscape for patients with metastatic renal cell carcinoma (mRCC), said Kathryn E. Beckermann, MD, PhD.
... to read the full story